Stock Events

Stock Events

Biomarin Pharmaceutical 

€45.6
204
-€0.01-0.02% Today

Statistics

Day High
45.6
Day Low
45.6
52W High
55.44
52W Low
43.86
Volume
-
Avg. Volume
-
Mkt Cap
8.77B
P/E Ratio
29.54
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.28
0.22
0.73
1.23
Expected EPS
0.724737
Actual EPS
N/A

Financials

10.96%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
5.54BRevenue
607.18MNet Income

Analyst Ratings

63.46Average Price Target
The highest estimate is 79.67.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
73%
Hold
27%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BM8.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.45B
Vertex Pharmaceuticals competes in the cystic fibrosis market, where both companies are looking for treatments that address the underlying cause of genetic diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.46B
Regeneron Pharmaceuticals is involved in genetic disorder treatments among other areas, competing with Biomarin in the broader biotech space.
AMGEN
AMGN
Mkt Cap185.74B
Amgen has a diverse biotech portfolio that includes treatments for genetic disorders, making it a competitor in the biopharmaceutical field.
Gilead Sciences
GILD
Mkt Cap161.85B
Gilead Sciences, with its focus on antiviral drugs and other treatments, competes for market share in the biopharmaceutical industry.
Novo Nordisk
NVO
Mkt Cap182.6B
Novo Nordisk specializes in diabetes and obesity treatments but is expanding into biopharmaceuticals for genetic diseases, competing with Biomarin.
Pfizer
PFE
Mkt Cap153.59B
Pfizer has a broad portfolio that includes a focus on rare diseases, making it a competitor in the same space as Biomarin.
Biogen
BIIB
Mkt Cap27.06B
Biogen focuses on neurological disorders and rare diseases, areas where Biomarin also seeks to make an impact, making them direct competitors.

About

There is no Profile data available for BM8.SG.
Show more...
CEO
Mr. Alexander Hardy
Employees
3221
Country
United States
ISIN
US09061G1013
WKN
000924801

Listings

MI
IT
1BMRN.MI
STU
DE
BM8.STU
SA
BR
B1MR34.SA
MX
MX
BMRN.MX

0 Comments

Share your thoughts

FAQ

What is Biomarin Pharmaceutical stock price today?▼
The current price of BM8.F is €45.6 EUR — it has decreased by -0.02% in the past 24 hours. Watch Biomarin Pharmaceutical stock price performance more closely on the chart.
What is Biomarin Pharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Biomarin Pharmaceutical stocks are traded under the ticker BM8.F.
Is Biomarin Pharmaceutical stock price growing?▼
BM8.F stock has fallen by -2.29% compared to the previous week, the month change is a -4.96% fall, over the last year Biomarin Pharmaceutical has showed a -17.15% decrease.
What is Biomarin Pharmaceutical market cap?▼
Today Biomarin Pharmaceutical has the market capitalization of 8.77B
When is the next Biomarin Pharmaceutical earnings date?▼
Biomarin Pharmaceutical is going to release the next earnings report on May 04, 2026.
What were Biomarin Pharmaceutical earnings last quarter?▼
BM8.F earnings for the last quarter are -0.2 EUR per share, whereas the estimation was 0.14 EUR resulting in a -241.66% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Biomarin Pharmaceutical revenue for the last year?▼
Biomarin Pharmaceutical revenue for the last year amounts to 5.54B EUR.
What is Biomarin Pharmaceutical net income for the last year?▼
BM8.F net income for the last year is 607.18M EUR.
How many employees does Biomarin Pharmaceutical have?▼
As of April 29, 2026, the company has 3,221 employees.
In which sector is Biomarin Pharmaceutical located?▼
Biomarin Pharmaceutical operates in the Health & Wellness sector.
When did Biomarin Pharmaceutical complete a stock split?▼
Biomarin Pharmaceutical has not had any recent stock splits.
Where is Biomarin Pharmaceutical headquartered?▼
Biomarin Pharmaceutical is headquartered in San Rafael, United States.